Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND AND AIM: The efficacy of pre-COVID-19 and post-COVID-19 infection 12-lead ECGs for identifying athletes with myopericarditis has never been reported. We aimed to assess the prevalence and significance of de-novo ECG changes following COVID-19 infection.
METHODS: In this multicentre observational study, between March 2020 and May 2022, we evaluated consecutive athletes with COVID-19 infection. Athletes exhibiting de-novo ECG changes underwent cardiovascular magnetic resonance (CMR) scans. One club mandated CMR scans for all players (n=30) following COVID-19 infection, despite the absence of cardiac symptoms or de-novo ECG changes.
RESULTS: 511 soccer players (median age 21 years, IQR 18-26 years) were included. 17 (3%) athletes demonstrated de-novo ECG changes, which included reduction in T-wave amplitude in the inferior and lateral leads (n=5), inferior leads (n=4) and lateral leads (n=4); inferior T-wave inversion (n=7); and ST-segment depression (n=2). 15 (88%) athletes with de-novo ECG changes revealed evidence of inflammatory cardiac sequelae. All 30 athletes who underwent a mandatory CMR scan had normal findings. Athletes revealing de-novo ECG changes had a higher prevalence of cardiac symptoms (71% vs 12%, p<0.0001) and longer median symptom duration (5 days, IQR 3-10) compared with athletes without de-novo ECG changes (2 days, IQR 1-3, p<0.001). Among athletes without cardiac symptoms, the additional yield of de-novo ECG changes to detect cardiac inflammation was 20%.
CONCLUSIONS: 3% of athletes demonstrated de-novo ECG changes post COVID-19 infection, of which 88% were diagnosed with cardiac inflammation. Most affected athletes exhibited cardiac symptoms; however, de-novo ECG changes contributed to a diagnosis of cardiac inflammation in 20% of athletes without cardiac symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Heart (British Cardiac Society) - 109(2023), 12 vom: 26. Mai, Seite 936-943 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Cardiomyopathies |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 08.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/heartjnl-2022-322211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355437589 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355437589 | ||
| 003 | DE-627 | ||
| 005 | 20231226064338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/heartjnl-2022-322211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355437589 | ||
| 035 | |a (NLM)37039240 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhatia, Raghav T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence and diagnostic significance of de-novo 12-lead ECG changes after COVID-19 infection in elite soccer players |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 08.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND AND AIM: The efficacy of pre-COVID-19 and post-COVID-19 infection 12-lead ECGs for identifying athletes with myopericarditis has never been reported. We aimed to assess the prevalence and significance of de-novo ECG changes following COVID-19 infection | ||
| 520 | |a METHODS: In this multicentre observational study, between March 2020 and May 2022, we evaluated consecutive athletes with COVID-19 infection. Athletes exhibiting de-novo ECG changes underwent cardiovascular magnetic resonance (CMR) scans. One club mandated CMR scans for all players (n=30) following COVID-19 infection, despite the absence of cardiac symptoms or de-novo ECG changes | ||
| 520 | |a RESULTS: 511 soccer players (median age 21 years, IQR 18-26 years) were included. 17 (3%) athletes demonstrated de-novo ECG changes, which included reduction in T-wave amplitude in the inferior and lateral leads (n=5), inferior leads (n=4) and lateral leads (n=4); inferior T-wave inversion (n=7); and ST-segment depression (n=2). 15 (88%) athletes with de-novo ECG changes revealed evidence of inflammatory cardiac sequelae. All 30 athletes who underwent a mandatory CMR scan had normal findings. Athletes revealing de-novo ECG changes had a higher prevalence of cardiac symptoms (71% vs 12%, p<0.0001) and longer median symptom duration (5 days, IQR 3-10) compared with athletes without de-novo ECG changes (2 days, IQR 1-3, p<0.001). Among athletes without cardiac symptoms, the additional yield of de-novo ECG changes to detect cardiac inflammation was 20% | ||
| 520 | |a CONCLUSIONS: 3% of athletes demonstrated de-novo ECG changes post COVID-19 infection, of which 88% were diagnosed with cardiac inflammation. Most affected athletes exhibited cardiac symptoms; however, de-novo ECG changes contributed to a diagnosis of cardiac inflammation in 20% of athletes without cardiac symptoms | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cardiomyopathies | |
| 650 | 4 | |a Electrocardiography | |
| 650 | 4 | |a Myocarditis | |
| 700 | 1 | |a Malhotra, Aneil |e verfasserin |4 aut | |
| 700 | 1 | |a MacLachlan, Hamish |e verfasserin |4 aut | |
| 700 | 1 | |a Gati, Sabiha |e verfasserin |4 aut | |
| 700 | 1 | |a Marwaha, Sarandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Chatrath, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Fyyaz, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Aleixo, Haroldo |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Turaihi, Samar |e verfasserin |4 aut | |
| 700 | 1 | |a Babu, Aswin |e verfasserin |4 aut | |
| 700 | 1 | |a Basu, Joyee |e verfasserin |4 aut | |
| 700 | 1 | |a Catterson, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Daems, Joelle J N |e verfasserin |4 aut | |
| 700 | 1 | |a Dhutia, Harshil |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Filipe |e verfasserin |4 aut | |
| 700 | 1 | |a van Hattum, Juliette C |e verfasserin |4 aut | |
| 700 | 1 | |a Iqbal, Zafar |e verfasserin |4 aut | |
| 700 | 1 | |a Kasiakogias, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Kenny, Antoinette |e verfasserin |4 aut | |
| 700 | 1 | |a Khanbhai, Tamim |e verfasserin |4 aut | |
| 700 | 1 | |a Khoury, Shafik |e verfasserin |4 aut | |
| 700 | 1 | |a Miles, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Oxborough, David |e verfasserin |4 aut | |
| 700 | 1 | |a Quazi, Kashif |e verfasserin |4 aut | |
| 700 | 1 | |a Rakhit, Dhrubo |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Anushka |e verfasserin |4 aut | |
| 700 | 1 | |a Varnava, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Tome Esteban, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Finocchiaro, Gherardo |e verfasserin |4 aut | |
| 700 | 1 | |a Stein, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Jorstad, Harald T |e verfasserin |4 aut | |
| 700 | 1 | |a Papadakis, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Sanjay |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart (British Cardiac Society) |d 1996 |g 109(2023), 12 vom: 26. Mai, Seite 936-943 |w (DE-627)NLM085989274 |x 1468-201X |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2023 |g number:12 |g day:26 |g month:05 |g pages:936-943 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/heartjnl-2022-322211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2023 |e 12 |b 26 |c 05 |h 936-943 | ||